Literature DB >> 24291608

Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry.

Leah C Jimmerson1, Jia-Hua Zheng1, Lane R Bushman1, Christine E MacBrayne1, Peter L Anderson1, Jennifer J Kiser2.   

Abstract

Efficient, inexpensive and sensitive assays for the measurement of drugs are of interest for pharmacokinetic and pharmacodynamics (PK-PD) analysis. Dried blood spots (DBS) are a unique bioanaltyical matrix with the potential to fulfill this interest for the measurement of numerous analytes. Here we describe the development and validation of a reversed-phase high performance liquid chromatographic (LC), tandem mass spectrometry (MS/MS) assay for the determination of ribavirin (RBV) in DBS. A 3mm punch from spotted and dried whole blood was extracted in methanol utilizing isotopically labeled internal standard for LC-MS/MS analysis. Validation was performed over a range of 0.05μg/mL to 10.0μg/mL and the method was shown to be precise (coefficient of variation ≤15%) and accurate (within ±15% of control). These acceptance criteria were met for hematocrit ranges of 20-54%, for center versus edge punches and for spot volumes from 10 to 60μL. RBV was stable for up to 140 days at room temperature and -20°C as well as for three freeze/thaw cycles. Correlation of RBV in DBS versus in plasma yielded r(2)≥0.98 demonstrating that DBS can be used as an alternative to plasma for PK-PD studies in human subjects.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALQ; Analytical method; DBS; Dried blood spot; HCT; Hepatitis C; LC–MS/MS; LLOQ; Nucleoside analog; PK–PD; QC; RBV; RT; Ribavirin; STD; UPH2O; above limit of quantitation; dried blood spots; hematocrit; liquid chromatography tandem–mass spectrometry; lower limit of quantitation; pharmacokinetics/dynamics; quality control; ribavirin; room temperature; standard; ultra-pure water

Mesh:

Substances:

Year:  2013        PMID: 24291608      PMCID: PMC3950646          DOI: 10.1016/j.jchromb.2013.10.035

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  14 in total

1.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.

Authors:  B K Matuszewski; M L Constanzer; C M Chavez-Eng
Journal:  Anal Chem       Date:  2003-07-01       Impact factor: 6.986

Review 2.  The analysis of dried blood spot samples using liquid chromatography tandem mass spectrometry.

Authors:  Brian G Keevil
Journal:  Clin Biochem       Date:  2010-07-01       Impact factor: 3.281

3.  Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry.

Authors:  Margareta Holub; Karin Tuschl; Rene Ratschmann; Kristina Anna Strnadová; Adolf Mühl; Georg Heinze; Wolfgang Sperl; Olaf A Bodamer
Journal:  Clin Chim Acta       Date:  2006-06-22       Impact factor: 3.786

4.  Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.

Authors:  C T Viswanathan; Surendra Bansal; Brian Booth; Anthony J DeStefano; Mark J Rose; Jeffrey Sailstad; Vinod P Shah; Jerome P Skelly; Patrick G Swann; Russell Weiner
Journal:  Pharm Res       Date:  2007-04-26       Impact factor: 4.200

Review 5.  Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules.

Authors:  Wenkui Li; Francis L S Tse
Journal:  Biomed Chromatogr       Date:  2010-01       Impact factor: 1.902

6.  Internal standard tracked dilution to overcome challenges in dried blood spots and robotic sample preparation for liquid chromatography/tandem mass spectrometry assays.

Authors:  Guowen Liu; Heidi M Snapp; Qin C Ji
Journal:  Rapid Commun Mass Spectrom       Date:  2011-05-15       Impact factor: 2.419

7.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Authors:  Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

Review 8.  The clinical pharmacology of ribavirin.

Authors:  P Glue
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

9.  Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.

Authors:  Lucie Durand-Gasselin; David Da Silva; Henri Benech; Alain Pruvost; Jacques Grassi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

10.  Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection.

Authors:  Arianna Loregian; Maria Cristina Scarpa; Silvana Pagni; Saverio Giuseppe Parisi; Giorgio Palù
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-06-02       Impact factor: 3.205

View more
  7 in total

1.  A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Authors:  Leah C Jimmerson; Lane R Bushman; Michelle L Ray; Peter L Anderson; Jennifer J Kiser
Journal:  Pharm Res       Date:  2016-09-15       Impact factor: 4.200

2.  Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.

Authors:  Joseph E Rower; Eric G Meissner; Leah C Jimmerson; Anu Osinusi; Zayani Sims; Tess Petersen; Lane R Bushman; Pamela Wolfe; John G McHutchison; Shyamasundaran Kottilil; Jennifer J Kiser
Journal:  J Antimicrob Chemother       Date:  2015-05-13       Impact factor: 5.790

3.  Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification.

Authors:  Leah C Jimmerson; Michelle L Ray; Lane R Bushman; Peter L Anderson; Brandon Klein; Joseph E Rower; Jia-Hua Zheng; Jennifer J Kiser
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-12-17       Impact factor: 3.205

4.  Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration.

Authors:  Kayla N Ellefsen; Jose Luiz da Costa; Marta Concheiro; Sebastien Anizan; Allan J Barnes; Sandrine Pirard; David A Gorelick; Marilyn A Huestis
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

Review 5.  Therapeutic drug monitoring by dried blood spot: progress to date and future directions.

Authors:  Abraham J Wilhelm; Jeroen C G den Burger; Eleonora L Swart
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

6.  Advantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing Process.

Authors:  Rosita Zakaria; Katrina J Allen; Jennifer J Koplin; Peter Roche; Ronda F Greaves
Journal:  EJIFCC       Date:  2016-12-01

Review 7.  Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues.

Authors:  Maria A Acquavia; Luca Foti; Raffaella Pascale; Antonia Nicolò; Vincenzo Brancaleone; Tommaso R I Cataldi; Giuseppe Martelli; Laura Scrano; Giuliana Bianco
Journal:  Talanta       Date:  2020-11-05       Impact factor: 6.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.